Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocytic leukemia
- 1 January 1981
Abstract
Interstitial lung disease has been reported in association with numerous alkylating agents and other chemotherapeutic drugs. Chlorambucil has only rarely been implicated in this complication. We report a case of a 74-year-old man with chronic lymphocytic leukemia who received high-dose intermittent chlorambucil and prednisone every two weeks. Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given. During the final episode, open lung biopsy was performed and demonstrated typical changes of drug-induced pneumonitis, with interstitial infiltrates and fibrosis and proliferation of type II alveolar lining cells.This publication has 15 references indexed in Scilit:
- Pulmonary histopathologic changes associated with melphalan therapyCancer, 1978
- Interstitial Pneumonia from MitomycinAnnals of Internal Medicine, 1978
- Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapyCancer, 1978
- Cytotoxic drug-induced lung diseaseThe American Journal of Medicine, 1977
- Pulmonary Effects of Radiation TherapyAnnals of Internal Medicine, 1977
- Cyclophosphamide therapy and interstitial pulmonary fibrosisCancer, 1976
- Busulphan toxicity syndrome caused by chlorambucil.BMJ, 1975
- Bi-weekly chlorambucil treatment of chronic lymphocytic leukemiaCancer, 1974
- The Spectrum of Drug-Induced Pulmonary DiseaseAnnals of Internal Medicine, 1972
- Busulphan lungThorax, 1969